MIAMI BEACH (EGMN) - Bevacizumab added to docetaxel and definitive radiotherapy was an effective and safe non-platinum-based regimen for locoregionally advanced squamous cell carcinoma of the head and neck in a small phase II trial that was presented at the annual meeting of the American Society for Radiation Oncology.The disease-free survival rate at 2 years (the primary end point) was 75% among 28 patients who had completed the full course of chemoradiation in the phase II study, said Dr. Nicholas...